Cargando…
Inhibition of MiR-199a-5p Reduced Cell Proliferation in Autosomal Dominant Polycystic Kidney Disease through Targeting CDKN1C
BACKGROUND: With a prevalence of about 1:500 to 1:1,000, autosomal dominant polycystic kidney disease (ADPKD) often causes renal failure, with many serious complications. However, there is no Food and Drug Administration (FDA) approved therapy available. MATERIAL/METHODS: MiR-199a-5p level in ADPKD...
Autores principales: | Sun, Lijun, Zhu, Jiaqi, Wu, Ming, Sun, Haipeng, Zhou, Chenchen, Fu, Lili, Xu, Chenggang, Mei, Changlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304454/ https://www.ncbi.nlm.nih.gov/pubmed/25588980 http://dx.doi.org/10.12659/MSM.892141 |
Ejemplares similares
-
Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials
por: Xue, Cheng, et al.
Publicado: (2015) -
Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease
por: Xu, Jing, et al.
Publicado: (2022) -
Clinical Characteristics and Disease Predictors of a Large Chinese Cohort of Patients with Autosomal Dominant Polycystic Kidney Disease
por: Chen, Dongping, et al.
Publicado: (2014) -
Autosomal dominant polycystic kidney
por: Gudadhe, Rugaved Raghavendra, et al.
Publicado: (2022) -
Autosomal dominant polycystic kidney disease combined with hypertrophic cardiomyopathy: A case report
por: Shen, Yingjing, et al.
Publicado: (2017)